Drug Patents owned by Biomarin Pharm

1. List of Kuvan drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8067416 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(1 year, 9 months from now)

US7566714 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(1 year, 9 months from now)

USRE43797 BIOMARIN PHARM Methods of administering tetrahydrobiopterin
Nov, 2024

(1 year, 9 months from now)

US9433624 BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
Nov, 2024

(1 year, 9 months from now)

US7612073 BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
Nov, 2024

(1 year, 9 months from now)

US8318745 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(1 year, 9 months from now)

US7727987 BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
Nov, 2024

(1 year, 9 months from now)

US7612073

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring
May, 2025

(2 years from now)

US7566714

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(2 years from now)

US7727987

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
May, 2025

(2 years from now)

US8067416

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(2 years from now)

USRE43797

(Pediatric)

BIOMARIN PHARM Methods of administering tetrahydrobiopterin
May, 2025

(2 years from now)

US8318745

(Pediatric)

BIOMARIN PHARM Crystalline forms of (6R)-L-erythro-tetrahydrobiopterin dihydrochloride
May, 2025

(2 years from now)

US9433624

(Pediatric)

BIOMARIN PHARM Methods and compositions for the treatment of metabolic disorders
May, 2025

(2 years from now)

US8003126 BIOMARIN PHARM Stable tablet formulation
Nov, 2025

(2 years from now)

US7566462 BIOMARIN PHARM Stable tablet formulation
Nov, 2025

(2 years from now)

US8003126

(Pediatric)

BIOMARIN PHARM Stable tablet formulation
May, 2026

(3 years from now)

US7566462

(Pediatric)

BIOMARIN PHARM Stable tablet formulation
May, 2026

(3 years from now)

US9216178 BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
Nov, 2032

(9 years from now)

US9216178

(Pediatric)

BIOMARIN PHARM Dry blend formulation of tetrahydrobiopterin
May, 2033

(10 years from now)

Drugs and Companies using SAPROPTERIN DIHYDROCHLORIDE ingredient

Market Authorisation Date: 19 December, 2013

Treatment: For reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine (phe) levels in patients with hyperphenylalaninemia (hpa); Method of use for reducing blood phenylalanine levels in a human suffering from hyperphenylalaninemia; To reduce blood phenylalanine levels in patients with hyperphenylalaninemia due to tetra hydrobiopterin responsive phenylketonuria. kuvan should be taken orally with food to increase absorption

Dosage: POWDER;ORAL

How can I launch a generic of KUVAN before it's patent expiration?
More Information on Dosage

2. List of Voxzogo drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8198242 BIOMARIN PHARM Variants of C-type natriuretic peptide
Jun, 2030

(7 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE48267 BIOMARIN PHARM Variants of C-type natriuretic peptide
May, 2030

(7 years from now)

US9907834 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Aug, 2036

(13 years from now)

US10646550 BIOMARIN PHARM Use of C-type natriuretic peptide variants to treat skeletal dysplasia
Aug, 2036

(13 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Nov 19, 2026

Drugs and Companies using VOSORITIDE ingredient

NCE-1 date: November, 2025

Market Authorisation Date: 19 November, 2021

Treatment: Use to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses

Dosage: POWDER;SUBCUTANEOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic